- Report
- February 2024
- 150 Pages
Global
From €4588EUR$4,750USD£3,923GBP
- Report
- August 2023
- 90 Pages
Global
From €4588EUR$4,750USD£3,923GBP
From €6279EUR$6,500USD£5,369GBP
- Report
- February 2024
- 150 Pages
Global
From €4588EUR$4,750USD£3,923GBP
- Report
- March 2024
- 200 Pages
Global
From €4009EUR$4,150USD£3,428GBP
- Report
- January 2024
- 200 Pages
Global
From €4009EUR$4,150USD£3,428GBP
- Report
- February 2024
- 90 Pages
Asia Pacific
From €4588EUR$4,750USD£3,923GBP
- Report
- February 2024
- 80 Pages
Latin America
From €4588EUR$4,750USD£3,923GBP
- Report
- February 2024
- 80 Pages
Europe
From €4588EUR$4,750USD£3,923GBP
- Report
- February 2024
- 70 Pages
United States
From €4588EUR$4,750USD£3,923GBP
- Report
- August 2023
- 70 Pages
Middle East, Africa
From €4588EUR$4,750USD£3,923GBP
- Report
- August 2023
- 150 Pages
North America
From €4588EUR$4,750USD£3,923GBP
- Report
- February 2021
- 500 Pages
United States
From €2318EUR$2,400USD£1,982GBP
- Report
- August 2020
- 250 Pages
Saudi Arabia
From €3477EUR$3,600USD£2,974GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4588EUR$4,750USD£3,923GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4588EUR$4,750USD£3,923GBP
- Report
- February 2024
- 70 Pages
Indonesia
From €4588EUR$4,750USD£3,923GBP
- Report
- February 2024
- 70 Pages
Philippines
From €4588EUR$4,750USD£3,923GBP
- Report
- February 2024
- 70 Pages
India
From €4588EUR$4,750USD£3,923GBP
- Report
- February 2024
- 70 Pages
Germany
From €4588EUR$4,750USD£3,923GBP
Sitagliptin is a drug used to treat endocrine and metabolic disorders. It is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which works by increasing the levels of incretin hormones in the body. These hormones help to regulate glucose levels in the blood, and can help to reduce the risk of developing type 2 diabetes. Sitagliptin is usually prescribed in combination with other drugs, such as metformin, to help control blood sugar levels. It is also used to treat other conditions, such as polycystic ovary syndrome and non-alcoholic fatty liver disease.
Sitagliptin is available in both oral and injectable forms, and is generally well tolerated with few side effects. It is a relatively new drug, and is becoming increasingly popular as a treatment for endocrine and metabolic disorders.
Some companies in the Sitagliptin market include Merck & Co., Inc., Novartis AG, and Takeda Pharmaceutical Company Limited. Show Less Read more